Astellas Turns Up Heat On Bid To Acquire CV Therapeutics
This article was originally published in PharmAsia News
Executive Summary
Following CV Therapeutics' refusal to accept its $16 per share purchase bid, Astellas is trying to turn up the pressure on CVT with a two-pronged approach involving both a tender offer for outstanding shares and a lawsuit in Delaware Chancery Court
You may also be interested in...
CV Therapeutics Again Declines Astellas $16 Per Share Purchase Offer
Less than a month after Astellas made public its bid to purchase CV Therapeutics for $16 a share for a total price of nearly $1 billion, CVT turned down the offer Feb. 20 as "significantly undervaluing" the biotech and not serving the best interests of the company or its stockholders
Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).